Finnország - finn - Fimea (Suomen lääkevirasto)

actavis group ptc ehf - valsartanum,amlodipini besilas - tabletti, kalvopäällysteinen - 10 mg / 160 mg - valsartaani ja amlodipiini

Finnország - finn - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - amlodipini besilas,valsartanum - tabletti, kalvopäällysteinen - 5 mg / 80 mg - valsartaani ja amlodipiini

Finnország - finn - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - amlodipini besilas,valsartanum - tabletti, kalvopäällysteinen - 5 mg / 160 mg - valsartaani ja amlodipiini

Finnország - finn - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - amlodipini besilas,valsartanum - tabletti, kalvopäällysteinen - 10 mg / 160 mg - valsartaani ja amlodipiini

Finnország - finn - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - fosaprepitant dimeglumine - infuusiokuiva-aine, liuosta varten - 150 mg - aprepitantti

Európai Unió - finn - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Finnország - finn - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - valsartanum,hydrochlorothiazidum,amlodipini besilas - tabletti, kalvopäällysteinen - 5 mg / 160 mg / 12.5 mg - valsartaani, amlodipiini ja hydroklooritiatsidi

Finnország - finn - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - hydrochlorothiazidum,amlodipini besilas,valsartanum - tabletti, kalvopäällysteinen - 10 mg / 160 mg / 12.5 mg - valsartaani, amlodipiini ja hydroklooritiatsidi

Finnország - finn - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - valsartanum,amlodipini besilas,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 5 mg / 160 mg / 25 mg - valsartaani, amlodipiini ja hydroklooritiatsidi

Finnország - finn - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - amlodipini besilas,hydrochlorothiazidum,valsartanum - tabletti, kalvopäällysteinen - 10 mg / 160 mg / 25 mg - valsartaani, amlodipiini ja hydroklooritiatsidi